<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:obo="http://purl.obolibrary.org/obo/"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/SIMVASTATIN-AMIODARONE-81642">
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_2663"/>
    <rdfs:comment>NLM-Corpus</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/lovastatin-ketoconazole-364">
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_40303"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>DIKB</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdfs:comment>ketoconazole is predicted to reduce the clearance of lovastatin by inhibition of CYP3A4</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/SIMVASTATIN-ITRACONAZOLE-78824">
    <rdfs:comment>Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_6076"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>Inhibition of simvastatin/ lovastatin metabolism by CYP3A4</rdfs:comment>
    <rdfs:comment>CredibleMeds</rdfs:comment>
    <rdfs:comment>Usually Avoid ·Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. ·Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. ·Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. ·Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine).</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/FLUVASTATIN-KETOCONAZOLE-78805">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_38561"/>
    <rdfs:comment>Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdfs:comment>Usually Avoid ·Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. ·Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. ·Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. ·Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine).</rdfs:comment>
    <rdfs:comment>Inhibition of simvastatin/ lovastatin metabolism by CYP3A4</rdfs:comment>
    <rdfs:comment>CredibleMeds</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/FLUVASTATIN-FLUCONAZOLE-26">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>DIKB</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_46081"/>
    <rdfs:comment>fluconazole increases the AUC of fluvastatin </rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_38561"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Lovastatin-Ketoconazole-82404">
    <rdfs:comment>ONC-HighPriority</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_40303"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_38545">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Simvastatin-Itraconazole-11490">
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_6076"/>
    <rdfs:comment>Drugbank</rdfs:comment>
    <rdfs:comment>Increased risk of myopathy/rhabdomyolysis|</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Simvastatin-Itraconazole-82988">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>ONC-HighPriority</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_6076"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Lovastatin-Ketoconazole-23279">
    <rdfs:comment>Drugbank</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_40303"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdfs:comment>Increased risk of myopathy/rhabdomyolysis|</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/simvastatin-diltiazem-210">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <rdfs:comment>DIKB</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
    <rdfs:comment>diltiazem is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/triazolam-diltiazem-219">
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9674"/>
    <rdfs:comment>diltiazem is predicted to reduce the clearance of triazolam by inhibition of CYP3A4</rdfs:comment>
    <rdfs:comment>DIKB</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Simvastatin-Amiodarone-5983">
    <rdfs:comment>Drugbank</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_2663"/>
    <rdfs:comment>Increased risk of rhabdomyolysis|</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Fluvastatin-Fluconazole-19816">
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_46081"/>
    <rdfs:comment>Fluconazole may increase the serum concentration of fluvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fluvastatin if fluconazole is initiated, discontinued or dose changed.|</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_38561"/>
    <rdfs:comment>Drugbank</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/rosuvastatin-fluconazole-444">
    <rdfs:comment>DIKB</rdfs:comment>
    <rdfs:comment>fluconazole is predicted to reduce the clearance of rosuvastatin by inhibition of CYP2C9</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_46081"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_38545"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Triazolam-Diltiazem-89138">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9674"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <rdfs:comment>OSCAR</rdfs:comment>
    <rdfs:comment>N</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/fluvastatin-fluconazole-476">
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_46081"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_38561"/>
    <rdfs:comment>fluconazole is predicted to reduce the clearance of fluvastatin by inhibition of CYP2C9</rdfs:comment>
    <rdfs:comment>DIKB</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Fluvastatin-Fluconazole-76338">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_38561"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_46081"/>
    <rdfs:comment>Kegg</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_38561">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/fluvastatin-ketoconazole-363">
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdfs:comment>ketoconazole is predicted to reduce the clearance of fluvastatin by inhibition of CYP3A4</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>DIKB</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_38561"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Rosuvastatin-Fluconazole-64583">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_46081"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_38545"/>
    <rdfs:comment>Kegg</rdfs:comment>
    <rdfs:comment>unclassified</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/fluvastatin-fluconazole-473">
    <rdfs:comment>DIKB</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_38561"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>fluconazole is predicted to reduce the clearance of fluvastatin by inhibition of CYP3A4</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_46081"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Rosuvastatin-Ketoconazole-64586">
    <rdfs:comment>unclassified</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_38545"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdfs:comment>Kegg</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/TRIAZOLAM-DILTIAZEM-1">
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9674"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>DIKB</rdfs:comment>
    <rdfs:comment>diltiazem increases the AUC of triazolam </rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/SIMVASTATIN-DILTIAZEM-37">
    <rdfs:comment>DIKB</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <rdfs:comment>diltiazem increases the AUC of simvastatin </rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Simvastatin-Diltiazem-16268">
    <rdfs:comment>Drugbank</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <rdfs:comment>Diltiazem may increase the serum concentration of simvastatin. Simvastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.|</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/simvastatin-itraconazole-190">
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_6076"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>DIKB</rdfs:comment>
    <rdfs:comment>itraconazole is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Atorvastatin-Ketoconazole-17416">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>Drugbank</rdfs:comment>
    <rdfs:comment>Increased risk of myopathy/rhabdomyolysis|</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_39548"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/SIMVASTATIN-Diltiazem-26569">
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
    <rdfs:comment>NDF-RT</rdfs:comment>
    <rdfs:comment>DILTIAZEM/SIMVASTATIN [VA Drug Interaction]</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Simvastatin-Diltiazem-82068">
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
    <rdfs:comment>ONC-HighPriority</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/TRIAZOLAM-Diltiazem-27011">
    <rdfs:comment>NDF-RT</rdfs:comment>
    <rdfs:comment>DILTIAZEM/TRIAZOLAM [VA Drug Interaction]</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9674"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/SIMVASTATIN-AMIODARONE-78798">
    <rdfs:comment>CredibleMeds</rdfs:comment>
    <rdfs:comment>Inhibition of metabolism of simvastatin/ lovastatin by CYP3A4</rdfs:comment>
    <rdfs:comment>Usually Avoid ·Consider Alternatives: Preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. Predisposing risk factors for rhabdomyolysis include advanced age (&gt;65 years), uncontrolled hypothyroidism, and renal impairment. ·Monitor: If alternative statins are not appropriate, monitor the patient for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine). The simvastatin dose should not exceed 20 mg/day in combination with amiodarone.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
    <rdfs:comment>Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_2663"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/atorvastatin-ketoconazole-362">
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdfs:comment>ketoconazole is predicted to reduce the clearance of atorvastatin by inhibition of CYP3A4</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>DIKB</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_39548"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Warfarin-Ketoconazole-17345">
    <rdfs:comment>Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed.|</rdfs:comment>
    <rdfs:comment>Drugbank</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_10033"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Warfarin-Ketoconazole-24340">
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>Drugbank</rdfs:comment>
    <rdfs:comment>Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed.|</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_10033"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Rosuvastatin-Ketoconazole-40112">
    <rdfs:comment>unclassified</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_38545"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdfs:comment>Kegg</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Simvastatin-DILTIAZEM-81643">
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <rdfs:comment>NLM-Corpus</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/ROSUVASTATIN-KETOCONAZOLE-78820">
    <rdfs:comment>Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>Inhibition of simvastatin/ lovastatin metabolism by CYP3A4</rdfs:comment>
    <rdfs:comment>Usually Avoid ·Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. ·Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. ·Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. ·Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine).</rdfs:comment>
    <rdfs:comment>CredibleMeds</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_38545"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/TRIAZOLAM-DILTIAZEM-79559">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>DDI-Corpus-2011</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9674"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_2663">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Lovastatin-Ketoconazole-24774">
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_40303"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdfs:comment>Increased risk of myopathy/rhabdomyolysis|</rdfs:comment>
    <rdfs:comment>Drugbank</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/LOVASTATIN-KETOCONAZOLE-78810">
    <rdfs:comment>CredibleMeds</rdfs:comment>
    <rdfs:comment>Inhibition of simvastatin/ lovastatin metabolism by CYP3A4</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_40303"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdfs:comment>Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis</rdfs:comment>
    <rdfs:comment>Usually Avoid ·Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. ·Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. ·Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. ·Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine).</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Simvastatin-Itraconazole-43751">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_6076"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
    <rdfs:comment>Kegg</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/simvastatin-amiodarone-623">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>DIKB</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_2663"/>
    <rdfs:comment>amiodarone is predicted to reduce the clearance of simvastatin by inhibition of CYP3A4</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Atorvastatin-Ketoconazole-24103">
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_39548"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>Drugbank</rdfs:comment>
    <rdfs:comment>Increased risk of myopathy/rhabdomyolysis|</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/TRIAZOLAM-DILTIAZEM-81264">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <rdfs:comment>DDI-Corpus-2013</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9674"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/LOVASTATIN-Ketoconazole-26357">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_40303"/>
    <rdfs:comment>NDF-RT</rdfs:comment>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
    <rdfs:comment>KETOCONAZOLE/LOVASTATIN [VA Drug Interaction]</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/TRIAZOLAM-DILTIAZEM-81670">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9674"/>
    <rdfs:comment>NLM-Corpus</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Simvastatin-Amiodarone-43774">
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_2663"/>
    <rdfs:comment>Kegg</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Simvastatin-Amiodarone-82210">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <rdfs:comment>ONC-HighPriority</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9150"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_2663"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/Triazolam-Diltiazem-23427">
    <rdfs:comment>Drugbank</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_101278"/>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_9674"/>
    <rdfs:comment>The calcium channel blocker, diltiazem, may increase the effect and toxicity of the benzodiazepine, triazolam.|</rdfs:comment>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_48339">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_40303">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_39548">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_101278">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_9674">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_10033">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_9150">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_6076">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/PRAVASTATIN-KETOCONAZOLE-78815">
    <rdfs:comment>CredibleMeds</rdfs:comment>
    <rdfs:comment>Usually Avoid ·Consider Alternative Antifungal Agents: Terbinafine or ciclopirox nail lacquer would be relatively safer antifungal agents. ·Consider Alternative Statins: For patients requiring long-term azole antifungal therapy, preferable statin alternatives include fluvastatin, rosuvastatin, or pravastatin. ·Temporarily Hold Statin Therapy: Temporarily holding the simvastatin/lovastatin during short-term (e.g., 2-week) azole antifungal therapy is a reasonable alternative for patients with stable cardiovascular disease. ·Monitor: If alternatives are not appropriate, the patient should be monitored for evidence of myopathy (muscle pain or weakness) and myoglobinuria (dark urine).</rdfs:comment>
    <rdfs:comment>Inhibition of simvastatin/ lovastatin metabolism by CYP3A4</rdfs:comment>
    <rdfs:comment>Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis</rdfs:comment>
    <obo:DIDEO_00000011 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_63618"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000000"/>
    <obo:DIDEO_00000014 rdf:resource="http://purl.obolibrary.org/obo/CHEBI_48339"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_63618">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://purl.obolibrary.org/obo/CHEBI_46081">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/CHEBI_24431"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DIDEO_00000019"/>
  </rdf:Description>
</rdf:RDF>
